Terlipressin Acetate Injection

A multicenter randomized controlled trial involving 200 patients showed that the treatment group with terlipressin (0.5-1.0 μ g/min continuous intravenous infusion) combined with low-dose dopamine (3-5 μ g/kg/min) had a 40% shorter improvement time in respiratory distress score (Borg scale) compared to the group treated with furosemide alone (median time 2.1 hours vs 3.5 hours), and a 35% reduction in 72 hour readmission rate (12% vs 18.5%). Mechanistically, by increasing peripheral vascular resistance (SVR), cardiac afterload is increased, while venous constriction enhances return blood volume, forming a "pressure volume" dual regulatory effect, rapidly relieving pulmonary congestion (PCWP decrease of 25% -30%) and tissue hypoperfusion (urine volume increase of 40% -50%).

Cardiac function optimization: By maintaining coronary artery perfusion pressure (CPP>60mmHg), the risk of myocardial ischemia is reduced, and the cardiac index (CI) is maintained at 2.5-3.0L/(min · m ²), while the oxygen delivery index (DO ₂ I) is increased by 20% -25% (from 550mL/(min · m ²) to 680mL/(min · m ²)).
Microcirculation protection: Animal experiments have shown that it can increase intestinal mucosal blood flow by 25% -30%, reduce lactate levels (from 4.2mmol/L to 2.8mmol/L), and improve tissue oxygenation.

Functional improvement: A 12-month follow-up study showed that in the group receiving terlipressin acetate injection (0.5mg subcutaneous injection, 3 times a week) combined with standard treatment (ACEI/ARB+beta blocker+aldosterone antagonist), LVEF increased by 5% -7% (from 32% to 38%) compared to baseline, and N-terminal B-type natriuretic peptide (NT proBNP) levels decreased by 30% -40% (from 2500pg/mL to 1500pg/mL).

Prognostic optimization: The all-cause mortality rate decreased by 18% (HR=0.82, 95% CI 0.71-0.95), and the readmission rate decreased by 22% (RR=0.78, 95% CI 0.69-0.89).

Improvement in exercise tolerance: Increase the diastolic velocity (e ') of the mitral annulus by 10% -15% (from 7cm/s to 8cm/s), reduce the E/e ratio by 20% -25% (from 15 to 11), reflecting an improvement in left ventricular filling pressure.
Collaborative management of comorbidities: In HFpEF patients with concomitant hypertension, the combination of calcium channel blockers (such as amlodipine) can increase the 6-minute walking distance by 50 meters (from 320m to 370m) and improve the quality of life score (MLHFQ) by 20%.

Vasoactive drug reduction: Reduce the dosage of norepinephrine by 40% -50% (from 0.2 μ g/kg/min to 0.1 μ g/kg/min) to avoid renal hypoperfusion caused by excessive vasoconstriction.

Clinical outcome improvement: A study involving 150 CABG patients showed that the incidence of POCS in the prophylactic use group was reduced by 40% (8% vs 13%) compared to the control group, and the hospitalization time was shortened by 2-3 days (median 7 days vs 10 days).
(2) Management of cardiac function recovery and rejection after heart transplantation

The anti-inflammatory effect of terlipressin acetate injection is not achieved through direct targeting of inflammatory factors. Instead, it blocks the amplification of inflammatory cascades and suppresses local and systemic inflammatory injury via multiple indirect pathways, including modulation of hemodynamic homeostasis, immune cell polarization, maintenance of intestinal barrier integrity, and regulation of core signaling pathways. This has become one of the cutting-edge research frontiers of the drug's pharmacology in recent years, and its mechanism has been validated in various organ injury models.First, the drug indirectly alleviates ischemic inflammatory injury in tissues by regulating splanchnic hemodynamic homeostasis.

It reduces ischemia-initiated inflammatory signaling at the source, indirectly inhibits the initial activation of inflammatory responses and decreases basal tissue inflammation levels. Multiple animal experiments have confirmed that the drug can significantly elevate mean arterial pressure in rat models of mesenteric ischemia, improve intestinal and renal perfusion, reduce ischemia-induced inflammatory infiltration, and lower organ inflammatory injury scores.

Second, modulation of macrophage polarization to suppress pro-inflammatory immune responses constitutes its core indirect anti-inflammatory mechanism.

It markedly downregulates mRNA and protein expression of M1 markers including iNOS and IL-1β and reduces the release of TNF-α, IL-6 and other pro-inflammatory cytokines, without interfering with basal M2 polarization.

Therefore, it effectively restores balanced immune polarization.Compared with the conventional vasopressor norepinephrine, terlipressin acetate presents prominent advantages in immunomodulation.

Latest advanced studies reveal that terlipressin acetate upregulates expression of VE-cadherin and PV-1 in intestinal vascular endothelial cells, restores intestinal endothelial integrity, reduces intestinal barrier permeability, and limits translocation of intestinal bacteria and endotoxins into the bloodstream. Consequently, it hinders endotoxin-triggered activation of the TLR4/NF-κB inflammatory pathway and prevents secondary inflammatory damage to distal organs such as the liver, kidneys and lungs.This indirect mechanism clarifies the organ-protective effect of the drug in severe enterogenic inflammation, breaks the traditional view that its action is confined to the circulatory system, and greatly expands the research scope of its anti-inflammatory applications.